Introduction
Despite the high cure rate and the remarkable progress in the development of effective treatment strategies, at least 20% of childhood acute lymphoblastic leukemia (ALL) patients in the developed countries still suffer from disease recurrence. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] Furthermore, treatment intensification increases the risk of treatment-related toxicity and may induce secondary malignancies. Extensive efforts have been made over the past two decades to identify factors that relate to prognosis and allow the adaptation of treatment intensity according to a patient's individual risk of treatment failure. Besides the risk factors associated with the host (for example, gender, age at diagnosis) and the leukemic clone (for example, white blood cell count at diagnosis, immunophenotype, structural and numeric chromosomal aberrations), measurement of in vivo treatment effectiveness, for example, prednisone response on day 8 of therapy, has proven to be the most important in the prediction of relapse. 11 Since the sensitivity of cytomorphological assessment of tumor cell reduction is limited to X5%, more sensitive methods have been developed, capable of detecting the degree of minimal residual disease (MRD) at a submicroscopic level of one leukemic cell among 10 4 -10 5 normal leukocytes (sensitivity level: 10 À4 -10
À5
; reviewed by Szczepanski 12 ). In most MRDbased treatment protocols, MRD has been analyzed by the detection of clonal immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangements, using real-time quantitative (RQ-PCR). 13, 14 Several childhood and adult ALL studies have indicated that the MRD detection during initial cytotoxic treatment is of great help in predicting the outcome. [15] [16] [17] [18] [19] [20] [21] [22] In the 1990s, a multicenter childhood ALL MRD study conducted by the International BFM (Berlin-Frankfurt-Mü nster) Study Group (I-BFM-SG) demonstrated that the monitoring of MRD at two consecutive time points (end of induction and end of consolidation) is useful in distinguishing a considerably sized group of patients with an excellent prognosis (standard risk, MRD-SR), which might benefit from treatment reduction, from the patients with an intermediate (intermediate risk, MRD-IR) or a particularly poor outcome (high risk, MRD-HR), with potential for improvement with treatment intensification including allogeneic stem cell transplantation or the application of new treatment strategies. 23 The 5-year relapse rates of each MRD-based risk group were 2% in SR (42.6% of patients), 22% in IR (42.6% of patients), and 80% in HR group (14.8% of patients).
On the basis of these results, the I-BFM-SG started a prospective international childhood therapy study (AIEOP-BFM ALL 2000) using RQ-PCR-based quantification of leukemic Ig/TCR gene rearrangements for risk-adapted patient stratification. The present report summarizes laboratory and clinical results for the requirements and feasibility of this approach in a large multicenter trial.
Patients, materials and methods

Patients and diagnosis
After obtaining informed consent, patients aged between 1 and 18 years who were first-time diagnosed with childhood ALL were recruited into the therapy study AIEOP-BFM ALL 2000. AIEOP-BFM ALL 2000 was approved by the respective institutional ethics committees. Diagnosis was confirmed using cytomorphology (FAB criteria) and cytochemistry when X25% of lymphoblastic cells were present in the bone marrow (BM), or when lymphoblasts were present in the peripheral blood (PB). Flow cytometric immunophenotyping was performed according to consensus protocols based on the guidelines proposed by the European Group for the Immunological Characterization of Leukemias. 24 The presence or absence of TEL/AML1, BCR/ABL, and MLL/AF4 fusion gene transcripts was analyzed as described previously. 25 Between 1 July 2000 (1 September 2000 for AIEOP) and 31 October 2004, a total of 3417 patients were eligible for the MRD analysis: 1660 patients from Germany, 1427 patients from Italy, 219 patients from Austria, and 111 patients from Switzerland. In 76 of these patients, no initial material (BM or PB at diagnosis) was available or diagnosis DNA could not be analyzed due to low quality or insufficient quantity.
Logistics of the study
To ensure standardized clinical stratification of patients, stringent requirements for shipping and processing of patient samples, frontline diagnostics and MRD measurement in centralized reference laboratories as well as rapid data transfer were developed by the study management and optimized in cooperation with the national trial centers and the local reference units (Figure 1 ). To guarantee on-time MRD-based risk group classification the study protocol included a 7-week time frame to perform complete MRD analysis. Depending on the logistics of DNA sampling and MRD measurement (at a single center in Austria and Switzerland, and two centers in Germany and Italy), final MRD quantification could be usually provided within 1-2 weeks after receiving BM samples collected at the two obligate follow-up time points.
Cell samples and DNA isolation BM samples were obtained at initial diagnosis and at the two consecutive follow-up time points day 33 (TP1) and day 78 (TP2) during the therapy (Figure 2 ). Mononuclear cells (MNCs) were isolated by Ficoll-Paque gradient centrifugation (Pharmacia, Freiburg, Germany) from BM samples followed by extraction of high-molecular weight DNA according to the standardized protocols using either the Puregene DNA isolation system (Gentra Systems, Minneapolis, MN, USA) or the Qiagen DNA Blood Kits (Qiagen, Hilden, Germany). 26 At diagnosis, X5 ml of BM aspirate was required generally corresponding to X1 Â 10 7
MNCs. At least 10 mg of diagnosis DNA was required for reliable MRD analysis of Ig/TCR gene rearrangements (Figure 3 ). The quality and quantity of genomic DNA derived from BM specimens was determined by spectrophotometer and confirmed by standardized RQ-PCR analysis of the control gene albumin. 27 In case of a dry tap at diagnosis, cell preparations from PB could be used, if the percentage of blasts was X40%. RQ-PCR-based MRD analysis of follow-up samples required X5 Â 10 6 MNCs of both obligatory MRD time points corresponding to a minimum of X5 mg of DNA.
Identification of PCR targets at diagnosis and design of allele-specific oligonucleotides
Genomic DNA samples at diagnosis were screened by PCR amplification using the BIOMED-1 primer sets for immunoglobulin kappa, IGK, deleting element (Kde) gene rearrangements (Vk-Kde, intron-Kde), complete and incomplete TCR delta, TCRD (Vd-(Dd)-Jd1, Dd2-Jd1, Vd2-Dd3, Dd2-Dd3), and TCR gamma, TCRG (Vg-Jg1.3/2.3, Vg-Jg1.1/2.1) rearrangements. Feasibility of MRD-based stratification in childhood ALL T Flohr et al in combination with one J H consensus primer. 29, 30 As an extra PCR target for T-ALL patients, primer sets to detect the SIL-TAL1/2 deletion were included in the PCR screening protocol utilizing breakpoint-spanning SIL gene forward and TAL gene reverse oligonucleotides. 28, 31 However, if no DNA rearrangements were identified for IGH, IGK-Kde, TCRG, TCRD, and SIL-TAL deletion, in a subset of patients alternative targets were added such as complete and incomplete TCRB (Vb-(Db)-Jb, Db-Jb), IGK (Vk-Jk), and IGL (Vl-Jl) using the respective BIOMED-2 multiplex PCR primer sets. 32 PCR products obtained from Ig and TCR gene rearrangements were further examined by heteroduplex or gene scanning analysis to discriminate between amplifications derived from monoclonal or polyclonal lymphoid cell populations. 32, 33 Biclonal or biallelic PCR products were separated either by cutting out amplicons from the polyacrylamide gel or by DNA cloning.
Junctional regions of monoclonal PCR products were sequenced using an ABI PRISM multicapillary fragment analyzer (Applied Biosystems, Darmstadt, Germany). Upon sequencing, patient-specific junctional region sequences of potential MRD PCR targets were identified using the IMGT (http://imgt.cines.fr), Vbase (http://vbase.mrc-cpe.cam.ac.uk), or IgBlast (www.ncbi. nlm.nih.gov/igblast/) databases and commonly distributed hardcopy sequences. At least one allele-specific oligonucleotide (ASO) primer was designed complementary to the junctional region sequence of each target either manually or using the Primer Express software (Applied Biosystems).
MRD PCR analysis and interpretation of MRD PCR results
MRD PCR targets were tested for specificity and sensitivity to enable on-time monitoring of remission samples. RQ-PCR analysis was performed either by using single PCR amplification with sequence-specific TaqMan hydrolysis probes or by a tworound nested RQ-PCR including SYBR Green I detection. 34, 35 The nested RQ-PCR used a first-round consensus touchdown PCR (starting at 66 1C) with a decreasing annealing temperature profile (À0.5 1C per cycle) over 28 cycles and 12 additional Feasibility of MRD-based stratification in childhood ALL T Flohr et al cycles at 52 1C, followed by the second-round RQ-PCR with a patient-specific ASO primer and an inner consensus primer. 34 RQ-PCR was performed on several platforms, that is, ABI PRISM Sequence Detection Systems 7000, 7700, or 7900 (Applied Biosystems) or the LightCycler (Roche Diagnostics, Mannheim, Germany). Tenfold serial dilutions of the diagnostic leukemic DNA sample were made in normal MNC DNA (pooled MNC DNA of six healthy donors) and used for RQ-PCR amplification in duplicate to generate a standard curve and to determine the sensitivity of the clone-specific Ig/TCR target. After receiving the follow-up samples, a freshly prepared dilution series was used to quantify the tumor load in triplicate in the patient's remission samples ( Figure 3 ). RQ-PCR settings and interpretation of realtime quantitative data were initially developed during several technical meetings of the I-BFM MRD Task Force. 36 Since the establishment of the European Study Group on MRD detection in ALL (ESG-MRD-ALL), these guidelines have been further optimized. 37 
MRD-directed risk group stratification
For reliable standard risk (MRD-SR) stratification, MRD negativity on treatment day 33 (TP1) and 78 (TP2) was required, based on at least two targets with sensitivities of p10 ) at TP2 were stratified in the MRD-HR group. MRD-IR stratification was feasible in case of positive MRD detection at either one or both time points but at a level o10 À3 at TP2. Upon the methodological development of quantitative TaqMan probebased 'real-time' PCR, the sensitivity of an RQ-PCR experiment was replaced by the quantitative range (QR) and the real cutoff value for MRD-HR assessment was adjusted to X5 Â 10 À4 based on a reproducible QR of at least 5 Â 10 À4 or higher. 37 Although these novel and independent MRD-based stratification criteria were introduced, established HR parameters were also retained: patients with prednisone poor response (PPR; X1000 leukemic blasts per microliter in PB on day 8), or non-remission to induction treatment (NRd33; X5% leukemic blasts in BM on day 33), or positivity for BCR/ABL or MLL/AF4 fusion gene transcripts. Such patients were treated in the high risk arm, independent of their MRD risk group assessment. 38, 39 Results
MRD PCR target availability and sensitivity in precursor-B-ALL patients
At least one Ig/TCR target could be identified in 98% of the 2854 analyzed precursor-B-ALL patients and two or more MRD PCR targets could be detected in 93% (Table 1) . Target-specific PCR analysis showed that IGH rearrangements could be found in 83% of patients, with the majority of recombinations represented by complete V H -J H joinings (76%), while incomplete D H -J H rearrangements were detected in 24% of patients (Figure 5a ), and both complete and incomplete rearrangements were identified in 17% of patients. IGK-Kde rearrangements (Vk-Kde or intron-Kde) could be found in 43% of patients (41% Vk-Kde, 13% intron-Kde; 11% showed both Kde joinings). TCRG rearrangements (Vg-Jg) were detected at an overall frequency of 53% while incomplete TCRD junctional regions were available in 46% of all patients (40% Vd2-Dd3, 19% Dd2-Dd3, and 13% showed both).
A total number of 5637 precursor-B-ALL targets were analyzed for sensitivity (Figure 5b Feasibility of MRD-based stratification in childhood ALL T Flohr et al targets, sensitivities of at least 10 À4 were reached. The percentages of sensitive targets (detection limit p10 À4 ) ranged from 71% for TCRG (Vg-Jg) to 92% for IGH complete V H -J H rearrangements. Taking into account target frequency and target sensitivity per patient, 2066 patients (72%) showed at least two sensitive MRD PCR targets (Table 1) . In 20% of patients only one sensitive target was available and in 8% no target with adequate sensitivity (detection limit p10 À4 ) could be obtained.
MRD PCR target availability and sensitivity in T-ALL patients
In 88% of all 422 analyzed T-ALL patients, two or more MRD PCR targets were detected, and at least one PCR target could be found in 93% of patients ( Table 1 ). The most frequent target group was represented by TCRG rearrangements (Vg-Jg) that were identified in 84% of patients (Figure 6a ). Complete TCRD rearrangements (Vd-Jd1) and the precursor Dd2-Jd1 were found in 38 and 11% of patients, respectively. Incomplete TCRD rearrangements (Vd2-Dd3 and Dd2-Dd3) occurred at significantly lower frequencies (p5%). The SIL-TAL deletion was identified in 7% of patients. Cross-lineage incomplete IGH (D H -J H ) rearrangements occurred in 12% of analyzed T-ALL patients, whereas complete IGH rearrangements were rarely detected (o1%). A total number of 654 T-ALL targets were analyzed for sensitivity (Figure 6b ). In 528 (81%) of these targets, sensitivities of at least 10 À4 were obtained. The SIL-TAL deletion and the TCRD rearrangements showed the highest proportions of sensitive targets (X90%). In case of TCRG and incomplete IGH (D H -J H ) rearrangements, sensitive targets were obtained in 74% of patients. Taking into consideration target frequency and target sensitivity per patient, at least two sensitive MRD-PCR markers could be identified in 260 patients (62%) ( Table 1) ; only one sensitive target was found in 22% of patients and no sensitive targets were available in 16% of T-ALLs.
MRD-based risk group classification
As shown in Figure 7 , PCR target identification was performed on the 98% (3341 of 3417) of ALL study patients who had sufficient high-quality DNA available at diagnosis. Among the 3341 initial diagnostic samples, no MRD PCR target was detected in 88 (3%), and in an additional 217 (7%) the identified PCR targets did not reach a sensitivity of 10 À4 . For 671 patients (20%), only one sensitive target could be identified, whereas in 2365 of 3341 (71%) patients at least two sensitive targets were available for MRD analysis. In the group of patients without sensitive targets, 26 of 217 (12%) patients became MRD classifiable due to the detection of high MRD values (X10 À3 ) at the second time point. However, most patients in this group could not be stratified because they appeared MRD-negative but lacked sensitive targets required for MRD-SR stratification. On the other hand, 266 of 671 (40%) patients with one sensitive target could be directly stratified into the MRD-IR or MRD-HR group because they showed positive MRD results ranging from 10 À4 /10 -5 (low positivity) up to higher levels. In this context, MRD-IR stratification was feasible if there was at least one additional target (detection limit 10 À3 ) available and MRD values measured with all targets were o10 À3 (TP2). MRD-HR stratification was indicated if any target available showed MRD X10 À3 at TP2 (definitions see Figure 4 ). The majority of patients with two sensitive targets (2302 of 2365 patients) could be MRD stratified according to their detectable disease level. Nevertheless, 63 patients of this category (2.7%) could not be stratified due to insufficient or no material available for at least one of the MRD time points. The overall results of the MRD-based stratification, as outlined in Figure 7 , revealed that 2594 of 3341 (78%) patients with MRD analysis performed could be classified based on MRD detection. Further details on the combined MRD information (TP1 and TP2) of these 2594 patients are shown in Table 2 . The remaining 747 patients, in whom MRD-directed stratification was not feasible, along with the 76 patients without adequate material at diagnosis, were stratified in the IR group unless conventional high risk factors, as defined in BFM ALL trial 95, were present. 38 The question of whether MRD-based treatment intervention is associated with improved outcome is to be answered by the evaluation of riskadapted treatment after there has been an adequate long-term follow-up of the patients.
MRD risk group distribution in the I-BFM-SG MRD studies 91/2000 and long-term event-free survival in I-BFM-SG MRD 91
The comparison between the MRD risk group distribution of the I-BFM-SG MRD study 91 and AIEOP-BFM ALL 2000 revealed statistically different results (P(w) ¼ 0.02). As shown in Table 3 , the MRD-SR groups in both the studies were comparable in size, whereas the MRD-HR group in AIEOP-BFM ALL 2000 was smaller (8.4 vs 14.8%) and the MRD-IR group was larger (51.9 vs 42.6%) in AIEOP-BFM ALL 2000 than in the I-BFM MRD study 91. 23 An updated life table analysis of the I-BFM-SG MRD study 91 is shown in Figure 8 . Outcome data of patients in the three MRD-defined risk groups comprising 10 years of observation revealed concordant results as compared to the previous 
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analysis: One additional late relapse was recorded in the MRD-IR group and two secondary malignancies (that is, brain tumors that occur 8.5 and 9.9 years after diagnosis in patients who received cranial irradiation during frontline therapy) occurred in the MRD-SR group. The median 10-year event-free survival (EFS) rate was 93% for MRD-SR patients, 74% for MRD-IR, and 16% for MRD-HR.
Discussion
The 3-year relapse-free survival of 129 childhood ALL patients in the I-BFM MRD study 91, with MRD information available at the two obligate time points, showed that the detection of MRD using Ig/TCR gene rearrangements during the first 3 months of induction therapy could discriminate outcome Time point not available for MRD analysis due to unavailable specimen or insufficient quantity of material. 
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T Flohr et al number of ALL patients. Stringent procedures for the exchange of material and information between the study centers and the local hospitals were also introduced. In addition to primer combinations available since the beginning of the study to investigate common Ig and TCR gene rearrangements, including IGH, IGK, TCRD, TCRG, and SIL-TAL deletion, primer sets for PCR analysis of additional IGK (Vk-Jk) and Ig lambda (IGL; Vl-Jl) targets as well as TCRB targets were implemented during the study. The Vk-Jk and Vl-Jl targets were used alternatively and were only temporarily included in the routine screening process. Since the contribution of these extra targets to overall target availability and sensitivity was limited, further testing of these light chain rearrangements was stopped and these were not included in the feasibility analysis. 43 The analysis of TCRB gene rearrangements (especially in T-ALL patients) contributed more to overall target availability and sensitivity but was not included in the MRD PCR target analysis because it was either introduced late in the study (in July 2003 in Germany and March 2004 in Italy) or not included (in Austria and Switzerland). 44 Ig/TCR target availability and sensitivity was tested in precursor-B as well as in T-ALL. In the case of precursor-B-ALL 98% of patients of this large series showed at least one target, and in 93% of all patients two targets could be identified. While the percentage of IgK, TCRD, and TCRG targets detected in our study was similar to that already reported, the percentage of all patients with identifiable IGH targets (83%) is lower than that in previous studies in childhood precursor-B-ALL, based on Southern blot and heteroduplex PCR analysis (490%).
14, 45 The discrepancy in the availability of V H -J H target can be partly explained by the fact that in our study some IGH-specific PCR products were found oligoclonal upon heteroduplex analysis and, for practical reasons, were not further characterized when other monoclonal co-rearrangements of IGK, TCRD, and TCRG could be preferentially used. In addition, if alternative Ig/TCR rearrangements were applicable, PCR screening was generally not repeated when the patient was negative for IGH targets. Furthermore, we were able to identify TCRB targets in 113 of 516 precursor-B-ALL patients screened (22%), a percentage relatively lower than that reported. 46 In 29% of these patients, TCRB recombinations could be used as alternative targets for MRD risk stratification, indicating that the add-on value in the routine use of this extra target in precursor-B-ALL seems to be limited. In summary, we confirmed in a large prospective and multicentric series the results from literature that the majority of precursor-B-ALL patients can be monitored using IGH, IGK (Vk-Kde), TCRG, and TCRD gene rearrangements, based on the frequency of their occurrences. 14, 47, 48 IGH rearrangements represented the most sensitive group of targets, which usually reached sensitivities p10
À4
, as also reported by others. 49 However, despite excellent RQ-PCR sensitivities, IGH gene loci were prone to oligoclonality in 30-40% of precursor-B-ALL, because of continuing and secondary rearrangement processes (reviewed by Szczepanski et al. 14 ) . Therefore, the use of oligoclonal Ig/TCR targets in MRD PCR analysis can lead to an underestimation of the leukemic tumor load because they might occur in a subclone of low frequency hence leading to potentially false-negative results. In consequence, IGH targets should routinely be used in combination with highly stable 'end-point rearrangements' suitable for sensitive MRD detection, that is, IGK-Kde rearrangements (especially Vk-Kde). 50 Using incomplete TCRD rearrangements as a third priority further increases the number of applicable MRD targets, as Vd2-Dd3 and Dd2-Dd3 recombinations show little clonal instability and good sensitivity. In contrast, TCRG rearrangements have proven to be less applicable in MRD detection in precursor-B-ALL, since their sensitivity is more frequently limited (410 À4 ) due to small junctional regions and non-specific amplification of TCR gene rearrangements in normal T-lymphocytes, as already reported. 51 Considering our results on target availability and sensitivity, we found the following priority order using antigen receptor gene rearrangements as MRD PCR targets in precursor-B-ALL, that is, IGH4IGK (Vk-Kde)4TCRD4TCRG and IGK (intron-Kde).
Also for T-ALL we obtained data in this large setting consistent with that in published results, 14 as we identified one target or two targets in 93 and 88% of analyzed T-ALL patients, respectively. While for TCRG (the most frequent group of targets, identifiable in 84% of patients) as well as for complete and incomplete TCRD 52, 53 or for incomplete IGH (D H -J H ) rearrangements, 54 frequencies are similar to previous reports, in our large series of T-ALL the frequency of SIL-TAL-positive patients was 7%, lower than the 12-26% in childhood T-ALL reported by others. 55 As a general observation, because of a different availability of targets, the number of patients without MRD-PCR targets at diagnosis was higher in T-ALL than that in precursor-B-ALL (7 vs 2%). Therefore, different from precursor-B-ALL, in T-ALL the additional screening of TCRB gene rearrangements was supposed to increase the availability of targets. From July 2003 to October 2004 we analyzed 70 T-ALL patients for the presence of TCRB gene rearrangements, and we identified at least one TCRB target in about 70% of these, a frequency slightly lower than that reported. 44 In 63% of the 70 T-ALL patients, at least one identified TCRB target was used as an essential target for MRD-based risk stratification in our study. In 54% of these cases TCRB rearrangements served as the second sensitive target (p10 À4 ) suitable for MRD-SR or MRD-IR classification. For this reason, the identification of TCRB rearrangements was implemented into the routine screening protocol to all T-ALL patients using the BIOMED-2 multiplex TCRB PCR assay. 32 The SIL-TAL deletion as well as complete/incomplete TCRD rearrangements comprised the most sensitive groups of targets, with sensitivity of p10 À4 in over 90% of cases. The SIL-TAL deletion is directly linked to the process of malignant transformation in T-ALL and it shows little background amplification in the PCR analysis, making it an ideal PCR marker for MRD detection. 31 In contrast to TCRD rearrangements, the junctions of TCRG and incomplete IGH rearrangements include less extensive non-templated nucleotide insertions, resulting in a significantly lower ratio of sensitive targets (about 75%). Taken together the results on target sensitivity in T-ALL, the following conclusion on the preferential use of MRD PCR targets can be drawn, that is, SIL-TAL4TCRD/TCRB4IGH (D H -J H )4TCRG.
In our study, MRD-based classification was feasible in 78% of patients. In approximately 90% of these patients, we have been able to use at least two sensitive PCR targets (p10 À4 ) for secure risk assessment (Figure 7) . However, 671 patients (20%) had only one sensitive target and 266 of these patients (40%) could be stratified according to the guidelines for MRD-derived risk group stratification (summarized in Figure 4 ). Therefore, lowering the stringency for feasible MRD-based stratification by requiring only one sensitive target instead of two would enable additional 405 study patients (12%) to benefit from MRD-based classification. According to the MRD kinetics in this group, based on one sensitive target, 248 of these 405 (61%) patients could have potentially been classified into the MRD-SR group, whereas 157 patients (39%) would have become MRD-IR. Consequently, using only one sensitive target in our study population would allow us to stratify X90% of patients at a sensitivity level of p10
À4 . This can be compared with MRD Feasibility of MRD-based stratification in childhood ALL T Flohr et al detection from studies based on flow cytometry (FCM), which demonstrated that FCM-mediated analysis is applicable in 495% of childhood ALL patients and allows MRD detection at 10 À4 in at least 90% of patients. 56 In the I-BFM MRD study 91, updated for this publication, we were able to identify a substantial number of patients with a very low risk of relapse and to define patients who had a very high probability of relapse while under current treatment protocols. The excellent 10-year follow-up results unequivocally show that long-term remission has remained stable over years, thus providing further validation for the concept of prospective MRD-PCR-based stratification. In AIEOP-BFM ALL 2000 we have utilized individual MRD information at predefined time points (day 33 and 78) for risk-adapted classification and almost completely replaced conventional risk variables by the measurement of response to therapy (on the basis of both prednisone and MRD) to select post-consolidation treatment intensity. MRD analysis allowed us to distinguish between an MRD-SR group with negative MRD results comprising 40% of the patients and an MRD-HR group with persisting high MRD values, comprising 8% of the patients. The remaining patients (52%) were stratified into the IR group. Despite the fact that in the I-BFM-SG MRD study 91, one sensitive marker was considered sufficient for MRD classification, the ratio of stratified patients in the MRD-SR groups was quite comparable in both the trials. 23 Interestingly, the MRD-HR group in AIEOP-BFM ALL 2000 was smaller (8.4%) than that in the I-BFM MRD study 91 (14.8%); that could comprise a random shift because of the low patient number in the I-BFM-SG MRD study 91. More likely, the discrepancy was due to treatment changes after TP1 which probably had influence on the MRD values measured at TP2. In the I-BFM-SG MRD study 91, induction treatment (and TP1) was immediately followed by a high-intensity element for all HR patients. In contrast, in AIEOP-BFM ALL 2000 after TP1, all HR patients were treated by consolidation protocol phase Ib (Figure 2 ), followed by BM aspiration for MRD evaluation of TP2, before entering the HR arm. Since it is well known that treatment modification in HR therapy can be very effective, 57, 58 these therapeutic changes might have had an impact on MRD levels measured at TP2 in AIEOP-BFM ALL 2000.
Furthermore, MRD monitoring and risk group classification revealed highly concordant results provided by all participating reference laboratories. In conclusion, the results of AIEOP-ALL BFM 2000 on 2594 childhood ALL patients, classifiable according to stringent MRD criteria, unambiguously demonstrate that risk stratification using Ig/TCR rearrangements as sensitive MRD-PCR targets is feasible in a large prospective international multicenter setting.
